EUDAW
EUDA Health Holdings LtdPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 27 EUDA Health Holdings Ltd received a deficiency notice from Nasdaq fo…
- X Sep 30 Short interest falls 27.7% to 12.0K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 0 added (0 new), 2 trimmed or exited.
- TrendDOWNTREND
3% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | $461.00 |
| Clear Street Group Inc. | TRIM | $2.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $27.2M |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 2 bullish · 1 bearish · 2 neutral- BULLISH 6-KJun 10, 2026
EUDA Health Holdings Ltd terminated its At The Market Offering Agreement with Chardan Capital…
The termination of the ATM agreement removes a significant overhang of potential dilution for EUDAW warrant holders. With no shares ever sold, the warrant's conversion value is protected from future…
- NEUTRAL 6-KJun 1, 2026
EUDA Health announced the launch of a new skincare product, the Regenixé iPSC-derived Skin Stem…
This is a routine product line extension with no disclosed financial terms. Monitor future quarterly filings for any revenue contribution from the Helixé line. Without sales data or guidance, this…
- BULLISH 6-KJun 1, 2026
EUDA Health Holdings Ltd regained compliance with Nasdaq's Minimum Market Value of Listed…
The delisting risk is resolved, removing a key overhang for the warrant (EUDAW). Monitor for any future compliance issues with other Nasdaq listing requirements, but this filing is a clear positive…
- NEUTRAL 6-KApr 28, 2026
EUDA Health announced that its partner Shenzhen Inno received approval under the Shenzhen Key…
This is a non-material event with no immediate financial impact. Monitor progress of TCR-T clinical development and any future distribution revenue from Malaysia. The 20-F filed concurrently…
All EUDAW filing & press-release reports (5)
- 6-K reportJun 10, 2026
- 6-K reportJun 1, 2026
- 6-K reportJun 1, 2026
- 6-K reportApr 28, 2026
- 6-K reportApr 27, 2026